

1 **Title: Profiling the cancer-prone microenvironment in a zebrafish model for MPNST**

2

3 **Supplementary Materials and Methods**

4

5 **Study population.** Experiments were performed with adult zebrafish. Zebrafish used for
6 precancerous and cancerous cohorts (*tg(sox10:RFP);brca2^{hg5/hg5};tp53^{zdf1/zdf1}*) were from separate
7 clutches derived from the same parents. The control cohort (*tg:sox10:RFP*)[1] was maintained as
8 a separate line. For precancerous and control cohorts, zebrafish were randomly selected from
9 their respective genotypic groups in approximately equal numbers of males and females.
10 Zebrafish for the cancer cohort were monitored for ONP tumor development and collected upon
11 tumor development. Specific details for age, sex, and animal numbers for the study population
12 are in **Table 1**. Ocular tumor specimens used for protein isolation were derived from
13 *tg(sox10:RFP);brca2^{hg5/hg5};tp53^{zdf1/zdf1}* zebrafish upon tumor development. Investigators were not
14 blinded to the genotype of animals used in this study. All animal studies were approved by the
15 Institutional Animal Care and Use Committee, North Carolina State University, Raleigh, NC and
16 by the Institutional Care and Use Committee, The Ohio State University, Columbus, OH. Animal
17 studies were performed in accordance with approved protocols and complied with ARRIVE
18 guidelines.

19

20 **Zebrafish husbandry.** Zebrafish used in this study were raised on a Z-Hab Duo recirculating
21 aquaculture system (Pentair, Apopka, FL, USA) and maintained on a 14-hour light/10-hour dark
22 cycle. The zebrafish colony undergoes routine sentinel testing and is negative for known zebrafish
23 pathogens. Live adult zebrafish were genotyped for the *brca2^{hg5}* mutation[2] at three months of
24 age by sequencing and were maintained as homozygous mutants for the *tp53^{zdf1}* mutation[3].
25 Carriers of the *sox10:RFP* transgene were identified in each generation by fluorescence
26 stereomicroscopy. All zebrafish collected for analysis were euthanized with Tricaine

27 methanesulfonate (300 mg/L) in system water buffered with Sodium Bicarbonate to a pH of ~7.0
28 or in an ice water slurry per our IACUC-approved Animal Study Protocol.

29

30 ***Tissue and fluorescence-activated cell sorting (FACS).*** The method for tissue dissociation
31 was modified from a previously published protocol[4]. Tissues from the optic nerve pathway
32 (**Table 1**) were dissected, placed in L-15 medium, and minced. Tissues were enzymatically
33 dissociated in 0.05% Trypsin/0.5 mM EDTA in sterile water at 28°C for 45 minutes with gentle
34 pipetting every 15 minutes. An equal volume of trypsin inhibitor solution (0.52 mg/ml Trypsin
35 inhibitor, type III-O, 3 mg/ml Bovine Serum Albumin, fraction V, and 0.004% DNase in L-15
36 medium) was added for trypsin inactivation. Samples were triturated three times with a 25-gauge
37 needle, filtered with a 35 um filter, and resuspended in cold FACS buffer (2% Fetal Bovine Serum
38 in 1X Hank's Buffered Saline Solution). Cell suspensions were stained with SYTOX Green Dead
39 Stain (Invitrogen) and analyzed with a MoFlo XDP Sorter (University of North Carolina Flow
40 Cytometry Core; Beckman Coulter, Brea, CA, USA) (**Fig. S1**). The MoFlo XDP Sorter was
41 maintained and calibrated daily according to the manufacturer's recommendation. Maximal
42 numbers of RFP-positive and RFP-negative populations were collected into L-15 medium,
43 pelleted, resuspended in QIAzol reagent (Qiagen, Germantown, MD, USA), and frozen on dry
44 ice.

45

46 ***RNA isolation, library preparation, and RNA sequencing.*** Total RNA from zebrafish specimens
47 was isolated with an miRNeasy Micro Kit (Qiagen, Germantown, MD, USA) according to the
48 manufacturer's protocol. RNA integrity, purity, and concentration, Illumina RNA library
49 construction, and sequencing were performed using total RNA (NC State University Genomic
50 Sciences Laboratory, Raleigh, NC) as previously described[5]. RNA-seq data has been deposited
51 at GEO and are publicly available as of the date of publication (GEO: GSE198220).

52

53 **Immunohistochemical analyses of zebrafish tissues.** Fifteen ONP cancers from
54 *brca2^{hg5/hg5};tp53^{zdf1/zdf1}* zebrafish that were collected and reported in a previous study[6] were used
55 for immunohistochemical analyses. Immunohistochemistry on unstained paraffin sections from
56 these specimens was performed as previously described[7, 8]. Zebrafish spleen and kidney were
57 used as positive controls for lcp1 and mpx1 expression, respectively (**Fig. S1D,E**). Normal brain
58 and eye provided internal positive controls for sox10 expression in cancer-bearing zebrafish (**Fig.**
59 **1B, Fig. S3P**). Sections incubated without primary antibodies were used as negative controls
60 (**Fig. S1H, Fig. S3Q**). Details on antibodies used are in **Table S4**.

61

62 **Immunohistochemical analyses of human tissues.** A commercially available tissue microarray
63 (TMA) composed of duplicate core biopsies from human peripheral nerve tumor tissues and
64 commercially available sections of normal human colon were used for immunohistochemical
65 analyses (#SO1001b, TissueArray.com LLC, Derwood, MD, USA). Due to the use of outdated
66 nomenclature in pathologic diagnoses provided by the manufacturer for some core specimens,
67 samples were designated as benign or malignant and are reported as such. The TMA included
68 22 cores from malignant tumors and 20 cores from benign tumors. Immunohistochemistry was
69 performed using a Bond Rxm autostainer (Leica Biosystems, Wetzlar, Germany) according to the
70 manufacturer's protocol with the following specifications: 15 minute antigen retrieval, pH 6.0; 15
71 minute incubation with primary antibody solution. Sections of normal human colon were
72 processed with and without primary antibody as within-run positive and negative assay controls,
73 respectively (**Fig. S6C**). A semiquantitative scale was used to assess the distribution and intensity
74 of antibody labeling in each core biopsy (**Fig. S6B**). Scoring was performed independently by
75 visual estimate by two veterinary pathologists (OMP, HRS) with final score determined in
76 consensus. Each core was scored individually for distribution and intensity of labeling and scores
77 were averaged for each pair of duplicates (**Fig S6B**). Details on antibodies used are in **Table S4**.

78

79 **RNA in situ hybridization analyses of zebrafish tissues.** RNA in situ hybridization was
80 performed using the RNAscope system (Advanced Cell Diagnostics (ACD), Newark, CA, USA)
81 using custom RNA probes for zebrafish *postna* and *postnb* designed by the manufacturer. The
82 RNAscope assay was performed on 5µm paraformaldehyde-fixed, paraffin-embedded tissue
83 sections using the 2.5 HD Duplex kit (ACD) according to the manufacturer's instructions with the
84 following modifications: slides were incubated with Target Retrieval and Protease Plus reagents
85 for 30 minutes and 30 minutes, respectively. A universal 2-plex negative control with probes
86 targeting the *dapB* gene (ACD) was used as a negative control. 2.5% Gills Hematoxylin was used
87 as a counterstain and slides were mounted using Vectamount medium.

88

89 **Tissue and slide imaging.** Zebrafish tissues used for IHC analyses were imaged with a Lumar
90 V12 stereomicroscope and Axiovision software (Zeiss, Baden-Wurtemberg, Germany). Digital
91 image files from histologic slides of zebrafish specimens were created by imaging with an
92 Olympus BX43 brightfield microscope with DP26 camera and Olympus cellSens Imaging
93 Software or by scanning with an Olympus VS200 Research Slide Scanner with Hamamatsu Orca
94 Fusion camera and Olympus OlyVIAViewer software (Olympus, Center Valley, PA, USA). Digital
95 image files from histologic slides of human specimens were created as whole slide images using
96 an AT2 digital slide scanner (Leica Biosystems). Zebrafish tissues used for RNA ISH analyses
97 were scanned at 63x magnification on an Aperio VERSA 8 (Leica Biosystems). Digital images
98 were minimally and globally processed with the GNU Image Manipulation Program for white
99 balance, contrast, and exposure.

100

101 **Human cell lines.** sNF96.2 cells were cultured at 37°C under 5% CO₂ in DMEM-HG (Gibco) with
102 10% (vol/vol) fetal calf serum (GeminiBio). sNF96.2 cells were obtained from the American Type
103 Culture Collection (Cat. #CRL-2884) and were not authenticated. JH2-002, St88 and S462 cells
104 were kindly provided by Drs. Jack Shern and Bega Murray (NCI CCR Pediatric Oncology Branch)

105 and were authenticated by STR profiling by the providers in December 2022. JH2-002, St88 and
106 S462 cells were cultured in RPMI (Gibco) with 10% (vol/vol) fetal calf serum (GeminiBio) and 1%
107 Pen/Strep (Gibco). All cell lines were were routinely tested for mycoplasma contamination using
108 a previously validated 16S rRNA-based mycoplasma group-specific PCR assay[9] or with the
109 MycoAlert Mycoplasma Detection Kit (Lonza Bioscience, Walkersville, MD, USA).

110

111 ***POSTN knockdown experiments.*** For siRNA experiments, cells were plated one day prior to
112 transfection. Cells were transfected with 15nM siRNA targeting POSTN (ON-TARGETplus Human
113 POSTN (10631) siRNA – SMARTpool; Cat. #L-020118-00-0005; Horizon Discovery, Cambridge,
114 UK) or control siRNA (ON-TARGETplus Non-targeting Pool; Cat. #D-001810-10-05; Horizon)
115 using Lipofectamine (Invitrogen) and incubated with siRNA/Lipofectamine for 48 hours. After 48
116 hours, the medium was replaced with fresh complete medium and cells were used for
117 experimental assays as show in **Fig. S8A**.

118

119 ***RNA extraction and quantitative RT-PCR analyses of human cell line samples.*** Total RNA
120 was isolated from human cell lines using Trizol (Invitrogen) according to the manufacturer's
121 protocol. RNA quantity and quality were assessed by spectrophotometry (NanoDrop ONE,
122 Waltham, MA, USA). 2 ug of total RNA was reverse-transcribed using High Capacity cDNA
123 Reverse Transcription Kit (Cat.# 4368814; Applied Biosystems) according to the manufacturer's
124 protocol. qRT-PCR analysis was performed with duplicate samples using SYBR green fluorescent
125 dye (Cat.# AZ-2350; Azura Genomics) and quantified with the ABI Prism 7900 sequence-
126 detection system (Applied Biosystems). Periostin (POSTN) gene expression was normalized to
127 the expression of the housekeeping gene Actin. When comparing mRNA expression between cell
128 lines treated with control or POSTN siRNA, gene expression was normalized to the cell line
129 treated with control siRNA.

Gene	Primer	Sequence
Actin	sense	5'-GAG CTA CGA GCT GCC TGA CG-3'
	antisense	5'-GTA GTT TCG TGG ATG CCA CAG-3'
POSTN	sense	5'-CAA CGC AGC GCT ATT CTG AC-3'
	antisense	5'-CCA AGT TGT CCC AAG CCT CA-3'

130

131

132 **Protein isolation from zebrafish and human tissues.** Ocular tumors from three

133 *tg(sox10:RFP);brca2^{hg5/hg5};tp53^{zdf1/zdf1}* were collected for protein isolation. Whole-cell lysates from

134 zebrafish ocular tumors or cultured cells were prepared by lysing cells in RIPA buffer (50 mM Tris

135 pH 7.4; 150 mM NaCl; 1mM EDTA; 1% Triton-X; 0.1% SDS) with complete protease inhibitors

136 (Roche, Indianapolis, IN, USA) and clarified by centrifugation. Tissue samples were homogenized

137 on ice with a motor-driven pestle during lysis. Anonymized frozen tumor samples derived from

138 human patients diagnosed with MPNST were acquired from the Ohio State University

139 Comprehensive Cancer Center Biospecimen Services Shared Resource. Frozen samples were

140 placed in RIPA buffer with complete protease inhibitors (Roche) and whole-cell lysates were

141 prepared by homogenizing tissues with a Precellys 24 tissue homogenizer (Bertin Technologies,

142 Montigny-le-Bretonneux, France) according to the manufacturer's protocol. Protein quantification

143 was performed by Bradford assay or by spectrophotometry (NanoDrop ONE; Abs = 280nm).

144

145 **Western blotting.** Whole-cell lysates were separated by SDS-polyacrylamide gel electrophoresis

146 in NuPAGE Bis-Tris precast gels in MOPS running buffer and electroblotted onto 0.45 μm PVDF

147 membranes using a wet transfer system. Membranes were incubated for one hour at room

148 temperature in in 5% w/v bovine serum albumin (BSA) in Tris-buffered saline-0.1% Tween-20

149 (TBST) or in 5% w/v non-fat dry milk in PBS-0.05% Tween-20 (PBST) and then incubated

150 overnight at 4°C with the primary antibody diluted in the same buffer used for blocking.

151 Membranes were washed four times in TBST or PBST and then incubated with the secondary

152 antibody in blocking buffer for one hour at room temperature. Membranes were rewashed four

153 times in TBST or PBST, incubated in a 1:3 mixture of ECL Pico WB Substrate and ECL Femto
154 Maximum Sensitivity substrate or in ECL Femto alone, and imaged with a ChemiDoc imager (Bio-
155 Rad Laboratories, Hercules, CA, USA) or Amersham Imager 600 (Cytiva, Marlborough, MA, USA)
156 using the chemiluminescence imaging function. For some western blots, sequential detection of
157 primary antibodies was performed on the membranes. In these cases, the membrane was
158 processed as described above, imaged, and subsequently washed before re-processing with the
159 next primary antibody. Details on antibodies used are in **Table S4**.

160

161 **Cell imaging and area measurement.** Cells were plated at a concentration of 2×10^4 cells/well
162 onto 18 mm diameter-coverslips and transfected with 15 nM POSTN siRNA or control siRNA as
163 described above. 48 hours after transfection, cells were fixed with 4% PFA in PBS for 10 minutes
164 at room temperature, washed in 1X PBS, and incubated with 1X Alexa Fluor™488 Phalloidin
165 (Cat. # A12379; Invitrogen) in PBS for 10 min at RT. Cells were washed once in 1X PBS, once in
166 dH₂O, and the coverslips were gently mounted on slides using a drop of VECTASHIELD®
167 Vibrance antifade mounting medium with DAPI (Cat. # H-1800; Vector Laboratories). Images were
168 acquired with a ZEISS Axio Imager.M2 upright microscope equipped with 5-megapixel
169 monochrome CMOS Axiocam 705 camera and processed with ZEN microscopy software. Single
170 cell area in μm^2 was measured in ImageJ by manually tracing the perimeter of 120 individual cells
171 per condition and proceeding to the analyze>measure>area Image-J function, after training Fiji
172 with the scalebar of ZEN software. The numbers of cells selected for analysis was based on a
173 review of literature reporting similar analytical studies in cultured cells. Samples were not
174 randomized, and researchers were not blinded during measurements and in experimental
175 condition assignment.

176

177 **Cell proliferation assays.** Cells were plated in triplicate in 24-well plates at a concentration of
178 4×10^4 cells/well (JH2-002, St88) or 2×10^4 cells/well (S462) and treated with 15 nM POSTN or

179 control siRNA as described above. After completion of transfection and media change, cells were
180 evaluated using an Incucyte S3 Live Cell Analysis System (Sartorius, Ann Arbor, MI) using 4h
181 interval scans for up to 5 days. Phase contrast images series were analyzed using Incucyte
182 software to measure the area in the well covered by cells and data were processed using
183 GraphPad Prism 10 (GraphPad Software, San Diego, CA, USA).

184

185 **MTT cell viability/cytotoxicity assay.** Cells were plated in 96 well plates at a concentration of
186 7,000 cells/well (JH2-002 and St88) or 5,000 cells/well (S462), with 16 replicates per condition,
187 and treated with 15 nM POSTN or control siRNA as described above. The day of the
188 measurement, 10 μ L of MTT solution (5 mg/mL dissolved in sterile water, Invitrogen Cat.# M6494)
189 was added to each well for each plate at collection timepoints indicated in **Fig. S8A**. Cells were
190 incubated with MTT for 2-3 hours at 37°C, 5% CO₂. After MTT incubation, the medium was gently
191 removed, and 100 μ L of pure DMSO was added to each well to dissolve the formazan crystals by
192 gentle pipetting, to prevent foaming. After a 15-minute incubation at 37°C, absorbance was
193 measured at 570 nm using Infinite® 200 PRO Tecan microplate reader with i-control™ software.

194

195 **EdU cell proliferation assay.** Cells were plated in 24-well plates at a concentration of 2×10^4
196 cells/well in triplicate and treated with POSTN or control siRNA as described above. After
197 completion of transfection and media change, cells were labeled with EdU according to the
198 manufacturer's protocol (Click-iT™ EdU Cell Proliferation Kit, Cat.# C10337; Invitrogen). After 2
199 hours incubation in 10 μ M EdU, cells were fixed in 4% PFA at room temperature for 15 minutes
200 and permeabilized with 0.1% Triton X-100 in PBS for 20 minutes at room temperature. The
201 incorporated EdU was labeled with the Click-iT reaction cocktail containing Alexa Fluor 488 azide
202 for 30 min at room temperature, protected from light. All cells were counterstained with Incucyte®
203 Nuclight Rapid Red Dye (Sartorius 4717). The green and red fluorescent images of labeled cells
204 were acquired using Incucyte S3 (Sartorius) at 10x magnification with exposure time 0.3 second

205 (green) and 0.4 second (red). The number of EdU-positive (green) cells and total cells (red) were
206 counted using the Incucyte analysis tool. The percentage of proliferating cells was represented
207 by the ratio of green cells to red cells.

208
209 **Statistical analyses for in vitro experiments.** GraphPad Prism version 10.2.3 for Mac
210 (GraphPad Software, San Diego, CA, USA) was used for graphical representation and statistical
211 analysis. The significance of differences among groups was evaluated with two-tailed Student's
212 t-test for comparisons between two groups, based on normality distribution checked by the
213 Shapiro-Wilk test. For datasets that did not follow a normal distribution, non-parametric tests like
214 the Mann-Whitney test for two groups comparisons and One Way ANOVA for three groups were
215 applied. Statistical significance was considered at a p-value ≤ 0.05 , with significance indicated as
216 * $p \leq 0.05$, ** $p \leq 0.005$, *** $p \leq 0.0005$, and **** $p \leq 0.0001$. Data are shown as mean or median
217 (where specified) \pm standard deviation (SD).

218
219 **Ingenuity Pathways Analysis (IPA).** Data were analyzed through the use of IPA[10] (QIAGEN
220 Inc.,
221 <https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis>; mapping database
222 version Q2 2020 and gene model source version Hg38/mm38 and Hg19/mm10 from UCSC). IPA
223 core analysis was performed with RNAseq data mapped to human gene names (generated as
224 described above). Data input settings for core analysis were as follows: reference set = user
225 dataset; \log_2 fold change cutoff = -1.0 to 1.0; adjusted p-value < 0.05. This allows for discovery
226 while limiting false discovery to 5%. Top pathways were identified by $-\log_{10}(\text{enrichment p-value})$
227 and activation z-score, where applicable, and were selected based on $-\log_{10}(\text{enrichment p-value})$
228 ≥ 1.3 and activation z-score (activated pathways, z-score ≥ 1.0 ; inhibited pathways, z-score $\leq -$
229 1.0). The complete list of canonical pathways identified is in **Table S1**. The complete list of
230 predicted upstream regulators is in **Table S2**.

231

232 The significance of the associations between data sets and canonical pathways was measured
233 as previously described[10]. Upstream regulators identified by IPA core analysis were filtered by
234 z-score, log₂ fold change, p-value, and predicted activation state. Upstream regulators predicted
235 to result in pathway activation were identified by z-score > 1.0, log₂ fold change > 1.0, and p-
236 value < 0.05. Upstream regulators predicted to result in pathway inhibition were identified by z-
237 score < -1.0, log₂ fold change < 1.0, and p-value < 0.05.

238

239 **GSEA analysis.** Gene sets for precancerous versus control microenvironments, cancer versus
240 control microenvironments, and cancer versus precancerous microenvironments were uploaded
241 to GSEA 4.3.3. Analysis was performed with the GSEA Preranked Tool using Hallmark Gene Sets
242 (H) with 1000 permutations and without gene set collapse. A false discovery rate (FDR) of <25%
243 was applied for statistical significance as directed in the GSEA User Guide. The complete list of
244 Hallmark gene sets with corresponding normalized enrichment score and FDR q-values is in
245 **Table S3.**

246 **References**

247

248 1 Blasky AJ, Pan L, Moens CB, Appel B. Pard3 regulates contact between neural crest
249 cells and the timing of Schwann cell differentiation but is not essential for neural crest
250 migration or myelination. *Dev Dyn* 2014; 243: 1511-1523.

251

252 2 Shive HR, West RR, Embree LJ, Azuma M, Sood R, Liu P, Hickstein DD. brca2 in
253 zebrafish ovarian development, spermatogenesis, and tumorigenesis. *Proc Natl Acad Sci U S A* 2010; 107: 19350-19355.

254

255 3 Berghmans S, Murphey RD, Wienholds E, Neuberg D, Kutok JL, Fletcher CD *et al.* tp53
256 mutant zebrafish develop malignant peripheral nerve sheath tumors. *Proc Natl Acad Sci U S A* 2005; 102: 407-412.

257

258 4 Bogler O. Isolation and purification of primary oligodendrocyte precursors. *Curr Protoc Neurosci* 2001; Chapter 3: Unit 3 4.

259

260 5 Arambula SE, Jima D, Patisaul HB. Prenatal bisphenol A (BPA) exposure alters the
261 transcriptome of the neonate rat amygdala in a sex-specific manner: a CLARITY-BPA
262 consortium study. *Neurotoxicology* 2018; 65: 207-220.

263

264 6 Mensah L, Ferguson JL, Shive HR. Genotypic and Phenotypic Variables Affect Meiotic
265 Cell Cycle Progression, Tumor Ploidy, and Cancer-Associated Mortality in a brca2-
266 Mutant Zebrafish Model. *J Oncol* 2019; 2019: 9218251.

267

268 7 Koupryanov VA, Selmek AA, Ferguson JL, Mo X, Shive HR. brca2-mutant zebrafish
269 exhibit context- and tissue-dependent alterations in cell phenotypes and response to
270 injury. *Sci Rep* 2022; 12: 883.

271

272 8 White LA, Sexton JM, Shive HR. Histologic and Immunohistochemical Analyses of Soft
273 Tissue Sarcomas From brca2-Mutant/ tp53-Mutant Zebrafish Are Consistent With Neural
274 Crest (Schwann Cell) Origin. *Vet Pathol* 2017; 54: 320-327.

275

276 9 van Kuppeveld FJ, Johansson KE, Galama JM, Kissing J, Bolske G, van der Logt JT,
277 Melchers WJ. Detection of mycoplasma contamination in cell cultures by a mycoplasma
278 group-specific PCR. *Appl Environ Microbiol* 1994; 60: 149-152.

279

280 10 Kramer A, Green J, Pollard J, Jr., Tugendreich S. Causal analysis approaches in
281 Ingenuity Pathway Analysis. *Bioinformatics* 2014; 30: 523-530.

282

283 11 Thisse B, Pflumio, S., Fürthauer, M., Loppin, B., Heyer, V., Degraeve, A., Woehl, R., Lux,
284 A., Steffan, T., Charbonnier, X.Q. and Thisse, C. Expression of the zebrafish genome
285 during embryogenesis (NIH R01 RR15402). ZFIN Direct Data Submission., 2001 edn.
286 The Zebrafish Information Network, 2001.

287

288 12 Thisse B, Thisse, C. Fast Release Clones: A High Throughput Expression Analysis. ZFIN
289 Direct Data Submission. The Zebrafish Information Network, 2004.

290

291 13 Kudo H, Amizuka N, Araki K, Inohaya K, Kudo A. Zebrafish periostin is required for the
292 adhesion of muscle fiber bundles to the myoseptum and for the differentiation of muscle
293 fibers. *Dev Biol* 2004; 267: 473-487.

294

295

296

297 **Supplementary Figure Legends**

298

299 **Figure S1. Zebrafish MPNST model characterization, gating strategy for fluorescence-**

300 **activated cell sorting, and immunohistochemical analyses.** A, Zebrafish ONP cancers exhibit

301 AKT and ERK1/2 activation. sNF96.2, human MPNST cell line. OT1, OT2, and OT3, ONP cancers

302 from *tg(sox10:RFP);brca2^{hg5/hg5};tp53^{zdf1/zdf1}* zebrafish. Cyclophilin B (CYPB) expression was used

303 as a loading control and this antibody did not detect zebrafish cypb. The membrane was cut into

304 sections for western blotting and reassembled for imaging. B-C, A similar gating strategy was

305 applied to control (not shown), precancerous (B), and cancer (C) specimens. Forward and side

306 scatter were used to eliminate debris and doublets. GFP expression (SYTOX Green Dead Stain;

307 Invitrogen) was used to exclude dead cells. Single live cells were subsequently sorted into RFP-

308 positive and RFP-negative populations. The final panels are also shown in **Fig. 1F**. D, lcp1

309 expression in zebrafish spleen (purple chromagen). E, mpx1 expression in zebrafish kidney

310 (purple chromagen). F, Lcp1-positive macrophages are present throughout the tumor and are

311 primarily concentrated along peripheral margins. G, Numerous mpx1-positive neutrophils are

312 distributed throughout the tumor, with limited overlap of lcp1 and mpx1 positivity. H, Negative

313 control incubated without primary antibody. Box 1 shows areas of melanin pigmentation.

314

315 **Figure S2. Site for tissue collection and experimental design.** A, Schematic of the zebrafish

316 head indicating the site for tissue collection from the orbit and major tissue types present in this

317 region. ON, optic nerve. Note that the bones comprising the orbit and skull are not shown as

318 individual structures for simplicity. B and C, Histologic sections from a wild type zebrafish

319 demonstrating the tissues present in the orbit and the bone margin surrounding the orbit (blue

320 arrows). Panels 1-3 in C are higher magnification images of the numbered regions in B. R, retina;

321 M, muscle; CR, choroid rete; A, adipose; B, brain; L, lens.

322

323 **Figure S3. ONP cancers from *brca2*^{hg5/hg5};*tp53*^{zdf1/zdf1} zebrafish exhibit widespread *sox10***
324 **expression.** A-O, 15 ONP cancers from *brca2*^{hg5/hg5};*tp53*^{zdf1/zdf1} that were described in a previous
325 study⁷ were analyzed for *sox10* expression (brown chromogen) by immunohistochemistry. The
326 boxed region in panel D is shown at higher magnification in **Fig. 1B**. P, Boxed region in panel O
327 showing *sox10*-positive cells in brain (internal positive control). Q, Negative control incubated
328 without primary antibody.

329

330 **Figure S4. Quality control analysis of RNAseq data.** A, Read counts for individual samples.
331 B, Cluster dendrogram of individual experimental replicates for each analyzed sample.

332

333 **Figure S5. Enriched canonical pathways that are shared across multiple comparisons.** The
334 pathways shown were identified as statistically significantly affected (see **Methods** for details). A,
335 Commonly enriched canonical pathways without predicted directional activity. B, Commonly
336 enriched pathways with predicted pathway activation. C, Commonly enriched pathways with
337 predicted pathway inhibition. PC ME, precancerous microenvironment; C ME, cancer
338 microenvironment; CTL ME, control microenvironment.

339

340 **Figure S6. Candidate gene testing in human MPNST samples.** A, Full Western blots for
341 expression of CTHRC1 and POSTN in MPNST samples from human patients. Blots were probed
342 for detection of CTHRC1 or POSTN and imaged, then washed and re-probed for detection of α -
343 tubulin. B, POSTN expression (brown chromogen) in a tissue microarray comprised of human
344 peripheral nerve tumor tissue. Solid outline, malignant tumor specimens (A1-E4); dashed line,
345 benign tumor specimens (E5-I4). Representative examples of various scoring outcomes in
346 individual core biopsies are shown. Graphical representations of scoring outcomes for distribution
347 and intensity show the scores for individual core biopsies, aligned in duplicate pairs. Red lines

348 connect unequal scores for duplicate pairs. C, POSTN expression (brown chromogen) in normal
349 human colon. The negative control was incubated with secondary antibody only.

350

351 **Figure S7. Expression of *postna* and *postnb* in zebrafish MPNSTs.** A, Validation of RNA
352 probes for *postna* (green chromogen) and *postnb* (red chromogen) in zebrafish embryos (4 days
353 post-fertilization). The site of highest *postna* expression is the pharyngeal cartilage (black
354 arrowheads), while highest sites of *postnb* expression include the skin (blue arrowheads) and
355 intersomitic regions (yellow arrowheads). These expression patterns are consistent with data
356 generated by large-scale analyses of gene expression in zebrafish embryonic and larval stages
357 by whole-mount in situ hybridization[11, 12] and an analysis of periostin in myoseptum
358 formation[13]. B, Moderate levels of *postna* and *postnb* expression in a zebrafish ONP cancer
359 specimen. Black arrowheads, interface between optic nerve (ON) and tumor (T). C, Rare *postna*
360 expression and low *postnb* expression in a zebrafish ONP cancer specimen. Black arrowheads,
361 interface between epithelium (E) and tumor (T).

362

363 **Figure S8. Periostin (POSTN) knockdown profoundly impacts MPNST cell morphology and**
364 **growth.** A, Timeline for experimental assays in MPNST cells treated with control (Ctrl) or POSTN
365 siRNA. B, POSTN expression remains knocked down for up to 144 hours post-transfection in
366 POSTN siRNA-treated cells compared to Ctrl siRNA-treated cells. C, POSTN knockdown
367 significantly reduces MPNST cell size, as quantified by cytoplasmic area, and drastically alters
368 cytoskeletal architecture (n = 120 cells per condition, imaged after 48 hours incubation with Ctrl
369 or POSTN siRNA). Data for JH2-002 and S462 cell lines are shown. D, POSTN knockdown
370 impairs MPNST cell growth by significantly reducing both cell viability and proliferative capacity.
371 Data for JH2-002 and S462 cell lines are shown. Significance, *p ≤ 0.05, **p ≤ 0.005, ***p ≤
372 0.0005, and ****p ≤ 0.0001.

373

374 **Figure S9. Uncropped western blots for expression of periostin (POSTN) in human MPNST**
375 **cell lines.** A, POSTN expression in parental JH2-002, St88, and S462 cell lines. Blots were
376 probed for detection of POSTN and imaged, then washed and re-probed for detection of α -tubulin.
377 The blot used for POSTN is shown at two different exposures due to the lower expression level
378 in S462 cells. B, POSTN expression 144 hours after transfection with POSTN siRNA or control
379 siRNA in JH2-002, St88, and S462 cell lines.









380

381 **Figure S10. Uncropped western blots for expression of periostin and integrin receptor**
382 **subunits after POSTN knockdown in human MPNST cell lines.** A, POSTN and integrin subunit
383 expression in JH2-002, St88, and S462 cell lines after treatment with control siRNA or POSTN
384 siRNA. Blots were sequentially probed for target detection with intervening washes between
385 primary antibodies. Due to the lower abundance of POSTN and integrin β 3 in S462 cells in
386 comparison to JH-002 and St88 cells, these blots were re-imaged after covering the lanes
387 containing lysates from JH-002 and St88 cells. Both full and partially covered blots are shown. B,
388 Blots used for detection of POSTN and integrins receptor subunits in C were re-probed for
389 detection of α -tubulin as a loading control.

390

Table S4. Antibodies used for immunohistochemistry and Western blotting experiments.

Antibody	Source	Identifier
anti-SOX10	GeneTex	Cat# GTX128374, RRID:AB_2885766
anti-Cyclophilin B	Cell Signaling Technology	Cat# 43603, RRID:AB_279924
anti-phospho-p44/42 MAPK(Erk1/2)(Thr202/Tyr204)	Cell Signaling Technology	Cat# 4370, RRID:AB_2315112
anti-p44/42 MAPK(Erk1/2)	Cell Signaling Technology	Cat# 4695, RRID:AB_390779
anti-phospho-AKT(Ser473)	Cell Signaling Technology	Cat# 4060, RRID:AB_2315049
anti-AKT (pan)	Cell Signaling Technology	Cat# 4691, RRID:AB_915783
anti-lcp1	GeneTex	Cat# GTX134697, RRID:AB_2887324
anti-mpx1	GeneTex	Cat# GTX128379, RRID:AB_2885768
anti-POSTN (used for analyses of human patient samples and tissue microarray)	GeneTex	Cat# GTX100602 RRID:AB_1951327
anti-POSTN (used for analyses of human MPNST cell lines)	Abcam	Cat# RM1074
Integrin antibody sampler kit	Cell Signaling Technology	Cat# 4749
anti-tubulin	Cell Signaling Technology	Cat# 38735
anti-rabbit (HRP-conjugated)	Cell Signaling Technology	Cat# 7074P2
anti-mouse (HRP-conjugated)	Cell Signaling Technology	Cat# 7076P2

Fig. S1






Fig. S2





Fig. S3

A Read count for individual samples



B Cluster dendrogram of experimental replicates





Fig. S4

A Commonly enriched canonical pathways without predicted directional activity




- PC ME vs. CTL ME**
C ME vs. CTL ME
- Signaling by Rho Family GTPases
 - RHOGL1 Signaling
 - Th1 and Th2 Activation Pathway
 - IL-13 Signaling Pathway
 - Chemokine Signaling
 - PAK Signaling
 - IL-12 Signaling and Production in Macrophages
 - T Cell Exhaustion Signaling Pathway
 - Antioxidant Action of Vitamin C
 - Virus Entry via Endocytic Pathways
 - Paxillin Signaling
 - Role of JAK1 and JAK3 in γ Cytokine Signaling
 - Pancreatic Adenocarcinoma Signaling
 - Role of Tissue Factor in Cancer

- C ME vs. CTL ME**
C ME vs. PC ME
- Phototransduction Pathway
 - Phagosome Maturation
 - Sphingosine-1-phosphate Signaling
 - Circadian Rhythm Signaling
 - Hepatic Fibrosis / Hepatic Stellate Cell Activation
 - IL-15 Production
 - Glycolysis I
 - Ephrin B Signaling
 - G Protein Signaling Mediated by Tubby
 - Iron homeostasis signaling pathway
 - Phagosome Formation
 - Corticotropin Releasing Hormone Signaling
 - Gq Signaling
 - P2Y Purigenic Receptor Signaling Pathway
 - GABA Receptor Signaling
 - Oxytocin Signaling Pathway
 - Gap Junction Signaling
 - STAT3 Pathway
 - CCR5 Signaling in Macrophages
 - Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis
 - Systemic Lupus Erythematosus In T Cell Signaling Pathway
 - Apelin Muscle Signaling Pathway
 - Cellular Effects of Sildenafil (Viagra)
 - Glioblastoma Multiforme Signaling
 - Tight Junction Signaling
 - Clathrin-mediated Endocytosis Signaling
 - Epithelial Adherens Junction Signaling
 - Apelin Adipocyte Signaling Pathway
 - SAPK/JNK Signaling
 - AMPK Signaling

- PC ME vs. CTL ME**
C ME vs. CTL ME
C ME vs. PC ME
- T Helper Cell Differentiation
 - RHOA Signaling
 - Agranulocyte Adhesion and Diapedesis
 - Antigen Presentation Pathway
 - Atherosclerosis Signaling
 - Molecular Mechanisms of Cancer
 - Granulocyte Adhesion and Diapedesis
 - Germ Cell-Sertoli Cell Junction Signaling
 - Regulation of the Epithelial-Mesenchymal Transition Pathway
 - Retin Signaling in Neurons
 - Axonal Guidance Signaling
 - Semaphorin Signaling in Neurons
 - Human Embryonic Stem Cell Pluripotency

B Commonly enriched activated canonical pathways




- PC ME vs. CTL ME**
C ME vs. CTL ME
- PKC θ Signaling in T Lymphocytes
 - Role of NFAT in Regulation of the Immune Response
 - CD28 Signaling in T Helper Cells
 - Cell Cycle Control of Chromosomal Replication
 - Kinetochores Metaphase Signaling Pathway
 - Natural Killer Cell Signaling
 - Crosstalk between Dendritic Cells and Natural Killer Cells
 - IL-7 Signaling Pathway
 - Dendritic Cell Maturation
 - GP6 Signaling Pathway
 - Th1 Pathway
 - IL-9 Signaling
 - Renin-Angiotensin Signaling
 - Cholecystokinin/Gastrin-mediated Signaling

- C ME vs. CTL ME**
C ME vs. PC ME
- TREM1 Signaling
 - Role of Hypercytokinemia/hyperchemokemia in the Pathogenesis of Influenza
 - Type 1 Diabetes Mellitus Signaling
 - Pyroptosis Signaling Pathway
 - Colanic Acid Building Blocks Biosynthesis
 - Macropinocytosis Signaling
 - Remodeling of Epithelial Adherens Junctions
 - Osteoarthritis Pathway
 - Actin Cytoskeleton Signaling
 - Tumor Microenvironment Pathway
 - Apelin Endothelial Signaling Pathway
 - Induction of Apoptosis by HIV1
 - Fc γ RIIB Signaling in B Lymphocytes
 - HIF1 α Signaling
 - Necroptosis Signaling Pathway
 - Wound Healing Signaling Pathway
 - N-acetylglucosamine Degradation II
 - Integrin Signaling
 - Role of PKR in Interferon Induction and Antiviral Response
 - FAT10 Signaling Pathway
 - Endothelin-1 Signaling
 - RAC Signaling
 - IL-8 Signaling
 - TWEAK Signaling
 - Role of MAPK Signaling in Promoting the Pathogenesis of Influenza
 - Gai Signaling
 - CCR3 Signaling in Eosinophils

- PC ME vs. CTL ME**
C ME vs. CTL ME
C ME vs. PC ME
- Systemic Lupus Erythematosus In B Cell Signaling Pathway
 - TEC Kinase Signaling
 - NF- κ B Signaling
 - Phospholipase C Signaling
 - Production of Nitric Oxide and Reactive Oxygen Species in Macrophages
 - Interferon Signaling
 - Actin Nucleation by ARP-WASP Complex
 - Neuroinflammation Signaling Pathway
 - Fc γ Receptor-mediated Phagocytosis in Macrophages and Monocytes
 - Glioma Invasiveness Signaling
 - Thrombin Signaling
 - fMLP Signaling in Neutrophils
 - CXCR4 Signaling
 - ILK Signaling
 - Leukocyte Extravasation Signaling
 - Regulation of Actin-based Motility by Rho
 - Ephrin Receptor Signaling
 - Activation of IRF by Cytosolic Pattern Recognition Receptors

C Commonly enriched inhibited canonical pathways




- PC ME vs. CTL ME**
C ME vs. CTL ME
- PD-1, PD-L1 cancer immunotherapy pathway
 - Regulation Of The Epithelial Mesenchymal Transition In Development Pathway

- C ME vs. CTL ME**
C ME vs. PC ME
- Calcium Signaling
 - White Adipose Tissue Browning Pathway
 - CREB Signaling in Neurons
 - Synaptogenesis Signaling Pathway
 - Netrin Signaling
 - Gustation Pathway
 - SNARE Signaling Pathway
 - Factors Promoting Cardiogenesis in Vertebrates
 - Dopamine-DARPP32 Feedback in cAMP Signaling
 - GPCR-Mediated Nutrient Sensing in Enterendocrine Cells
 - Neuropathic Pain Signaling In Dorsal Horn Neurons
 - WNT/Ca⁺ pathway
 - Oxytocin In Spinal Neurons Signaling Pathway
 - Neurovascular Coupling Signaling Pathway
 - Synaptic Long Term Depression
 - Cardiac β -adrenergic Signaling
 - Glutamate Receptor Signaling
 - Endocannabinoid Neuronal Synapse Pathway
 - Huntington's Disease Signaling
 - Dilated Cardiomyopathy Signaling Pathway
 - Role of NFAT in Cardiac Hypertrophy
 - GNRH Signaling
 - Sperm Motility
 - Protein Kinase A Signaling
 - Gas Signaling
 - Oxytocin In Brain Signaling Pathway
 - G-Protein Coupled Receptor Signaling
 - Opioid Signaling Pathway
 - Breast Cancer Regulation by Slathmin1
 - FAK Signaling
 - Cardiac Hypertrophy Signaling (Enhanced)
 - Synaptic Long Term Potentiation
 - Semaphorin Neuronal Repulsive Signaling Pathway
 - LXR/RXR Activation


Fig. S5

A Candidate gene testing in human MPNST samples



B Immunohistochemistry for POSTN Human peripheral nerve tumor tissue microarray

A1-E4: Malignant
 E5-I4: Benign
 I5-J10: Normal nerve (not scored)
 ‡ TMA standard internal control (not scored)






Scoring for POSTN distribution

% positive area	Score
<10% sample	0
10-25%	1
25-50%	2
50-75%	3
75-100%	4

Scoring for POSTN intensity

Labeling intensity	Score
Minimal/absent	0
Weak	1
Moderate	2
Intense	3



C Immunohistochemistry for POSTN Control specimens






Fig. S6

A Probe validation for *postna* and *postnb*



B Moderate *postna* and *postnb* expression in a zebrafish ONP cancer specimen



C Rare *postna* expression and low *postnb* expression in a zebrafish ONP cancer specimen







Fig. S7




B POSTN knockdown persists up to 144 hours post-transfection



C POSTN knockdown reduces MPNST cell size and alters cytoskeletal morphology



D POSTN knockdown impairs MPNST growth by inducing cytotoxicity and reducing proliferation



A POSTN expression in human MPNST cells






Fig. S9

B POSTN knockdown persists up to 144 hours post-transfection





B Expression of loading control protein α -tubulin in human MPNST cells for blots shown in panel B

